Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis

作者：Wu, Cheng; Liu, Lijie; Zhao, Peng; Tang, Dan; Yao, Dingkang; Zhu, Liang; Wang, Zhiqiang^*

来源：Gut and Liver, 2015, 9(5): 665-671.

DOI：10.5009/gnl14212

• Chronic hepatic lesions
• Proteomics
• Diagnosis
• Surface-enhanced laser desorption/ionization
• Biological markers

Background/Aims: To screen for serum protein/peptide biomarkers Of hepatitis B virus (HBV)-associated chronic hepatic lesions in an attempt to profile the progression of HBV-associated chronic hepatic lesions using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) techniques. Methods: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers. The most valuable SELDI peak for predicting the progression to LC in HBV-infected patients was identified. Results: A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1. Conclusions: The peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.

• 出版日期2015-9
• 单位中国人民解放军总医院; 中国人民解放军第二军医大学; 天津市中医药研究院附属医院